Editas Medicine

Pioneering CRISPR researcher Jennifer Doudna is coming to Disrupt

Jennifer Doudna, a woman whose work has triggered the explosion in innovation in the field of synthetic biology and has given researchers around the world a way to program and reprogram the living wor

Up to $818 million deal between J&J and Locus Biosciences points to a new path for CRISPR therapies

The up to $818 million deal between Locus Biosciences and Janssen Pharmaceuticals (a division of Johnson & Johnson) that was announced yesterday points toward a new path for CRISPR gene editing te

Oral arguments for who owns CRISPR-Cas9 start next month

The date has been set for oral arguments to begin over who owns the patent rights to the gene-editing wonder CRISPR-Cas9. Berkeley’s Jennifer Doudna and her colleague from the Max Planck Institu

CRISPR loses Nobel to tiny machines

CRISPR, the gene-editing technology revolutionizing the biotech industry, has failed to take home the Nobel prize in chemistry for the second year in a row. Instead, the award went to Jean-Pierre Sauv

Reshaping human health and changing lives through gene editing

Gene editing is going to fundamentally change our lives and how we traditionally think about health throughout the first half of the 21st century. The question isn’t "When will gene editing become a

Editas biotech stock drops by 26 percent over CRISPR patent dispute

Gene editing outfit Editas has been one of the most successful tech IPOs of 2016 so far, with shares skyrocketing up 130 percent shortly after the company’s public debut. But the stock has now

Biotech Startups Hit the Ground Running, With Six Filing IPO Plans Today

If we had to gamble on it, we’d bet the IPO market will be far more brisk this year than last year, which was the worst year for tech IPOs in particular since 2009. Even still, it came as a b